During the two past decades, atrial fibrillation (AF) has become a major public health problem. With 33.5 million patients worldwide, AF is the most common arrhythmia in adults. Accordingly, the $ 4.9 Bn AF device market is growing at 15.6% CAGR.
Building on 15+ years of research, Volta Medical has investigated a therapeutic product using data-driven AI approach for optimal real-time guidance during atrial fibrillation (AF) interventions. Our product has the potential to revolutionize AF interventions in drastically improving both procedural workflow and clinical outcomes. Notably, Volta’s product has been tested clinically with extremely promising results. Our first product is entirely ready for approval and does not need further development.
Volta’s Unique Selling Proposition relies on its cost efficiency and allows for a decrease in procedure time.
Volta has raised € 2.3 million and recruited top talents in AI. Also, Volta has hired top-level executives who bring decades of healthcare industry experience.